JP2016224056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016224056A5 JP2016224056A5 JP2016138684A JP2016138684A JP2016224056A5 JP 2016224056 A5 JP2016224056 A5 JP 2016224056A5 JP 2016138684 A JP2016138684 A JP 2016138684A JP 2016138684 A JP2016138684 A JP 2016138684A JP 2016224056 A5 JP2016224056 A5 JP 2016224056A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- patient
- dfmo
- sulindac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229920000768 polyamine Polymers 0.000 claims 6
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 6
- 229960000894 sulindac Drugs 0.000 claims 6
- 235000005911 diet Nutrition 0.000 claims 4
- 230000000378 dietary effect Effects 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 3
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 3
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000002271 resection Methods 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 201000002758 colorectal adenoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- 229940063675 spermine Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34504810P | 2010-05-14 | 2010-05-14 | |
| US61/345,048 | 2010-05-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510342A Division JP6083646B2 (ja) | 2010-05-14 | 2011-05-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016224056A JP2016224056A (ja) | 2016-12-28 |
| JP2016224056A5 true JP2016224056A5 (enExample) | 2017-03-02 |
Family
ID=44915003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510342A Expired - Fee Related JP6083646B2 (ja) | 2010-05-14 | 2011-05-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| JP2016138684A Pending JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510342A Expired - Fee Related JP6083646B2 (ja) | 2010-05-14 | 2011-05-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130217743A1 (enExample) |
| EP (1) | EP2568978B1 (enExample) |
| JP (2) | JP6083646B2 (enExample) |
| CA (1) | CA2799431A1 (enExample) |
| WO (1) | WO2011143579A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| LT2912193T (lt) | 2012-10-29 | 2018-12-27 | Arizona Board Of Regents On Behalf Of University Of Arizona | Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi |
| WO2015195120A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| US12042477B2 (en) | 2016-02-23 | 2024-07-23 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| JP2023528930A (ja) | 2020-06-04 | 2023-07-06 | フェス・セラピューティクス，インコーポレーテッド | がんを処置する個別化された方法 |
| WO2023081612A1 (en) * | 2021-11-02 | 2023-05-11 | Cancer Prevention Pharmaceuticals, Inc. | Methods of treating patients having type 1 diabetes with eflornithine |
| EP4618967A1 (en) * | 2022-11-20 | 2025-09-24 | Universität Zürich | Combination of polyamine pathway inhibitor drug and proline/arginine diet restriction |
| CN115976243A (zh) * | 2023-02-27 | 2023-04-18 | 贵州医科大学 | 口服阿司匹林及阿托伐他汀出现的肠道菌群标志物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2706255B1 (fr) * | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| EP1067919A1 (en) | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo and sulindac combination in cancer chemoprevention |
| JP2004506683A (ja) * | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する |
| PT2430452E (pt) * | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
-
2011
- 2011-05-13 CA CA 2799431 patent/CA2799431A1/en not_active Abandoned
- 2011-05-13 EP EP11781359.2A patent/EP2568978B1/en not_active Not-in-force
- 2011-05-13 JP JP2013510342A patent/JP6083646B2/ja not_active Expired - Fee Related
- 2011-05-13 US US13/697,984 patent/US20130217743A1/en not_active Abandoned
- 2011-05-13 WO PCT/US2011/036464 patent/WO2011143579A2/en not_active Ceased
-
2016
- 2016-07-13 JP JP2016138684A patent/JP2016224056A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016224056A5 (enExample) | ||
| Cascinu et al. | Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| Xia et al. | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) | |
| del Bufalo et al. | Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent | |
| Muñoz et al. | The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists | |
| Fowles et al. | Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma | |
| ES2931337T3 (es) | Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red | |
| JP2018508469A5 (enExample) | ||
| Fury et al. | A phase 1 study of everolimus+ weekly cisplatin+ intensity modulated radiation therapy in head-and-neck cancer | |
| ES2890424T3 (es) | Selección de neoepítopos como objetivos específicos de enfermedad para terapia con eficacia mejorada | |
| ES2882223T3 (es) | 17Alfa-valerato de cortexolona para el uso en el tratamiento de tumores | |
| JP2013528376A5 (enExample) | ||
| Fateeva et al. | Current state of melanoma therapy and next steps: battling therapeutic resistance | |
| JP2017501381A5 (enExample) | ||
| Wang et al. | New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints | |
| JP2016525097A5 (enExample) | ||
| ES2900825T3 (es) | Método de tratamiento adyuvante para el cáncer | |
| JP2016515615A5 (enExample) | ||
| ES2813877T3 (es) | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos | |
| JP2016519157A (ja) | ガネテスピブを用いる特定癌の治療レジメン | |
| Butt et al. | BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series | |
| JP2018530568A5 (enExample) | ||
| AU2020326612B2 (en) | Treatment of canine cancers | |
| JP2017515806A5 (enExample) | ||
| Castellani et al. | Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib |